Symbols / JSPR $0.88 -2.64% Jasper Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
JSPR Chart
About

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 24.52M
Enterprise Value -24.01M Income -91.02M Sales —
Book/sh 0.41 Cash/sh 1.82 Dividend Yield —
Payout 0.00% Employees 27 IPO —
P/E — Forward P/E -0.59 PEG —
P/S — P/B 2.12 P/C —
EV/EBITDA 0.27 EV/Sales — Quick Ratio 2.42
Current Ratio 2.59 Debt/Eq 14.72 LT Debt/Eq —
EPS (ttm) -5.82 EPS next Y -1.49 EPS Growth —
Revenue Growth — Earnings 2026-05-12 ROA -72.92%
ROE -191.12% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 27.98M
Shs Float 21.87M Short Float 11.23% Short Ratio 8.57
Short Interest — 52W High 7.19 52W Low 0.81
Beta 3.12 Avg Volume 598.24K Volume 642.22K
Target Price $8.70 Recom Buy Prev Close $0.90
Price $0.88 Change -2.64%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.70
Mean price target
2. Current target
$0.88
Latest analyst target
3. DCF / Fair value
$-35.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.88
Low
$1.50
High
$20.00
Mean
$8.70

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-11 main RBC Capital Sector Perform → Sector Perform $4
2025-09-22 main Evercore ISI Group Outperform → Outperform $14
2025-09-22 main JMP Securities Market Outperform → Market Outperform $6
2025-09-22 main BTIG Buy → Buy $7
2025-08-15 main UBS Buy → Buy $25
2025-07-08 down BMO Capital Outperform → Market Perform $4
2025-07-08 main JMP Securities Market Outperform → Market Outperform $12
2025-07-08 main Evercore ISI Group Outperform → Outperform $20
2025-07-07 down William Blair Outperform → Market Perform —
2025-07-07 main HC Wainwright & Co. Buy → Buy $20
2025-07-07 down Cantor Fitzgerald Overweight → Neutral —
2025-07-07 main BTIG Buy → Buy $20
2025-05-15 main Oppenheimer Outperform → Outperform $65
2025-05-13 main UBS Buy → Buy $33
2025-03-11 reit HC Wainwright & Co. Buy → Buy $40
2025-02-13 init UBS — → Buy $38
2025-01-10 reit JMP Securities Market Outperform → Market Outperform $70
2025-01-10 main HC Wainwright & Co. Buy → Buy $40
2025-01-09 main RBC Capital Outperform → Outperform $48
2025-01-06 main JMP Securities Market Outperform → Market Outperform $70
News
RSS: Latest JSPR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-09-22 MARTELL RONALD A Chief Executive Officer — 41,000 $2.43 $99,630
2025-09-22 WIGGANS THOMAS G Director — 41,000 $2.43 $99,630
2025-09-22 LUCAS SVETLANA Director — 20,000 $2.43 $48,600
2025-09-22 SHIZURU JUDITH ANNE M.D., PH.D. Director — 41,000 $2.43 $99,630
2024-12-12 MAHAL JEETINDER SINGH Chief Operating Officer — 900 $7.10 $6,390
2024-12-12 MAHAL JEETINDER SINGH Chief Operating Officer — 900 $22.11 $19,899
2024-09-12 MAHAL JEETINDER SINGH Chief Operating Officer — 900 $7.10 $6,390
2024-09-12 MAHAL JEETINDER SINGH Chief Operating Officer — 900 $21.23 $19,104
2024-06-12 MAHAL JEETINDER SINGH Chief Operating Officer — 900 $7.10 $6,390
2024-06-12 MAHAL JEETINDER SINGH Chief Operating Officer — 900 $24.16 $21,740
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
76.24
+10.71%
68.86
+34.50%
51.20
+38.99%
36.83
Research And Development
55.82
+7.79%
51.78
+49.55%
34.63
+36.21%
25.42
Selling General And Administration
20.42
+19.57%
17.08
+3.06%
16.57
+45.19%
11.41
General And Administrative Expense
20.42
+19.57%
17.08
+3.06%
16.57
+45.19%
11.41
Other Gand A
20.42
+19.57%
17.08
+3.06%
16.57
+45.19%
11.41
Total Expenses
76.24
+10.71%
68.86
+34.50%
51.20
+38.99%
36.83
Operating Income
-76.24
-10.71%
-68.86
-34.50%
-51.20
-38.99%
-36.83
Total Operating Income As Reported
-76.24
-10.71%
-68.86
-34.50%
-51.20
-38.99%
-36.83
EBITDA
-74.87
-10.50%
-67.75
-34.91%
-50.22
-37.76%
-36.46
Normalized EBITDA
-74.87
-11.41%
-67.20
-6.41%
-63.15
-47.77%
-42.73
Reconciled Depreciation
1.37
+23.92%
1.11
+13.64%
0.97
+158.62%
0.38
EBIT
-76.24
-10.71%
-68.86
-34.50%
-51.20
-38.99%
-36.83
Total Unusual Items
0.00
+100.00%
-0.56
-104.31%
12.93
+105.94%
6.28
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-0.56
-104.31%
12.93
+105.94%
6.28
Special Income Charges
0.00
-100.00%
0.02
-99.69%
5.72
-38.29%
9.28
Restructuring And Mergern Acquisition
0.00
+100.00%
-0.02
+99.69%
-5.72
+38.29%
-9.28
Net Income
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Pretax Income
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Net Non Operating Interest Income Expense
5.06
-2.71%
5.20
+641.65%
0.70
—
Net Interest Income
5.06
-2.71%
5.20
+641.65%
0.70
—
Interest Income Non Operating
5.06
-2.71%
5.20
+641.65%
0.70
—
Interest Income
5.06
-2.71%
5.20
+641.65%
0.70
—
Other Income Expense
-0.09
+89.04%
-0.80
-106.27%
12.81
+106.75%
6.20
Other Non Operating Income Expenses
-0.09
+64.23%
-0.25
-113.91%
-0.12
-43.75%
-0.08
Gain On Sale Of Security
—
-0.57
-107.99%
7.20
+339.92%
-3.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Net Income From Continuing Operation Net Minority Interest
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Net Income From Continuing And Discontinued Operation
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Net Income Continuous Operations
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Normalized Income
-71.27
-11.52%
-63.91
-26.28%
-50.61
-37.11%
-36.91
Net Income Common Stockholders
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Diluted EPS
-4.89
+20.87%
-6.18
+40.00%
-10.30
+61.71%
-26.90
Basic EPS
-4.89
+20.87%
-6.18
+40.00%
-10.30
+61.71%
-26.90
Basic Average Shares
14.58
+39.71%
10.44
+186.14%
3.65
+220.20%
1.14
Diluted Average Shares
14.58
+39.71%
10.44
+186.14%
3.65
+220.20%
1.14
Diluted NI Availto Com Stockholders
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Line Item Trend 2023-12-31
Total Assets
94.89
Current Assets
88.94
Cash Cash Equivalents And Short Term Investments
86.89
Cash And Cash Equivalents
86.89
Receivables
0.25
Other Receivables
—
Taxes Receivable
0.25
Prepaid Assets
1.51
Other Current Assets
0.29
Total Non Current Assets
5.95
Net PPE
4.19
Gross PPE
6.65
Accumulated Depreciation
-2.46
Properties
0.00
Machinery Furniture Equipment
0.74
Other Properties
3.44
Leases
2.48
Other Non Current Assets
1.76
Total Liabilities Net Minority Interest
16.45
Current Liabilities
12.37
Payables And Accrued Expenses
9.32
Payables
4.15
Accounts Payable
4.15
Current Accrued Expenses
5.17
Employee Benefits
0.00
Pensionand Other Post Retirement Benefit Plans Current
1.77
Current Debt And Capital Lease Obligation
0.97
Current Capital Lease Obligation
0.97
Other Current Liabilities
0.32
Total Non Current Liabilities Net Minority Interest
4.08
Long Term Debt And Capital Lease Obligation
1.81
Long Term Capital Lease Obligation
1.81
Long Term Provisions
—
Tradeand Other Payables Non Current
—
Other Non Current Liabilities
2.26
Preferred Securities Outside Stock Equity
—
Stockholders Equity
78.44
Common Stock Equity
78.44
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
11.16
Ordinary Shares Number
11.16
Treasury Shares Number
0.00
Additional Paid In Capital
248.04
Retained Earnings
-169.60
Total Equity Gross Minority Interest
78.44
Total Capitalization
78.44
Working Capital
76.56
Invested Capital
78.44
Total Debt
2.79
Capital Lease Obligations
2.79
Net Tangible Assets
78.44
Tangible Book Value
78.44
Derivative Product Liabilities
0.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-62.60
-20.23%
-52.07
-13.54%
-45.86
-36.17%
-33.68
Cash Flow From Continuing Operating Activities
-62.60
-20.23%
-52.07
-13.54%
-45.86
-36.17%
-33.68
Net Income From Continuing Operations
-71.27
-10.55%
-64.47
-71.06%
-37.69
-23.00%
-30.64
Depreciation Amortization Depletion
1.37
+23.92%
1.11
+13.64%
0.97
+158.62%
0.38
Depreciation And Amortization
1.37
+23.92%
1.11
+13.64%
0.97
+158.62%
0.38
Other Non Cash Items
0.49
+22.44%
0.40
+107.44%
-5.39
+40.69%
-9.09
Stock Based Compensation
6.62
+27.02%
5.21
+27.38%
4.09
+290.36%
1.05
Operating Gains Losses
0.01
-98.09%
0.57
+107.99%
-7.20
-339.92%
3.00
Gain Loss On Investment Securities
—
0.57
+107.99%
-7.20
-339.92%
3.00
Gain Loss On Sale Of PPE
0.01
0.00
—
—
Change In Working Capital
0.17
-96.61%
5.10
+886.29%
-0.65
-140.04%
1.62
Change In Receivables
0.00
-100.00%
0.66
+200.00%
-0.66
-210.50%
0.60
Change In Prepaid Assets
-2.12
-376.79%
0.77
+145.83%
0.31
+114.10%
-2.21
Change In Payables And Accrued Expense
2.75
-47.21%
5.20
+495.59%
-1.31
-133.74%
3.90
Change In Accrued Expense
2.87
+1.67%
2.82
+237.44%
0.84
-12.83%
0.96
Change In Payable
-0.12
-105.12%
2.38
+210.69%
-2.15
-173.21%
2.94
Change In Account Payable
-0.12
-105.12%
2.38
+210.69%
-2.15
-173.21%
2.94
Change In Other Current Assets
0.52
+189.55%
-0.58
-412.28%
-0.11
+67.15%
-0.35
Change In Other Current Liabilities
-0.97
-2.96%
-0.94
-183.55%
1.13
+456.78%
-0.32
Investing Cash Flow
-0.53
-99.25%
-0.27
+53.65%
-0.58
+76.28%
-2.43
Cash Flow From Continuing Investing Activities
-0.53
-99.25%
-0.27
+53.65%
-0.58
+76.28%
-2.43
Net PPE Purchase And Sale
-0.53
-99.25%
-0.27
+53.65%
-0.58
+76.28%
-2.43
Purchase Of PPE
-0.55
-106.74%
-0.27
+53.65%
-0.58
+76.28%
-2.43
Sale Of PPE
0.02
0.00
—
—
Capital Expenditure
-0.55
-106.74%
-0.27
+53.65%
-0.58
+76.28%
-2.43
Financing Cash Flow
47.88
-52.58%
100.97
+183483.64%
0.06
-99.95%
100.97
Cash Flow From Continuing Financing Activities
47.88
-52.58%
100.97
+183483.64%
0.06
-99.95%
100.97
Net Common Stock Issuance
47.20
-53.49%
101.48
0.00
—
Proceeds From Stock Option Exercised
0.69
+52.43%
0.45
+721.82%
0.06
-76.69%
0.24
Net Other Financing Charges
—
-0.96
—
89.98
Changes In Cash
-15.25
-131.35%
48.64
+204.87%
-46.38
-171.50%
64.86
Beginning Cash Position
87.30
+125.78%
38.67
-54.53%
85.05
+321.37%
20.18
End Cash Position
72.05
-17.47%
87.30
+125.78%
38.67
-54.53%
85.05
Free Cash Flow
-63.15
-20.67%
-52.33
-12.71%
-46.43
-28.60%
-36.11
Common Stock Issuance
47.20
-53.49%
101.48
0.00
—
Issuance Of Capital Stock
47.20
-53.49%
101.48
0.00
-100.00%
10.75
Net Preferred Stock Issuance
—
—
0.00
-100.00%
10.75
Preferred Stock Issuance
—
—
0.00
-100.00%
10.75
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category